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Abstract 
Background: Intravenous artesunate has replaced quinine as the first‑line therapy for severe imported malaria, given 
its anti‑malarial superiority shown in clinical trials conducted in endemic countries. Evidence for red blood cell (RBC) 
exchange in patients with severe malaria treated with artesunate is lacking. This retrospective cohort study describes 
the experience at Hospital Clinic of Barcelona with the use of artesunate for severe malaria and the joint use of RBC 
exchange in selected cases.
Methods: Patients treated for severe malaria at Hospital Clinic of Barcelona between August 2013 and January 2015 
were included in this retrospective study. Severe malaria was defined according to WHO criteria. Data were extracted 
from electronic hospital records. A log‑linear mixed model approach was used to estimate parasite clearance times.
Results: Within the study period, 42 patients were diagnosed of malaria at this centre, of which 38 had Plasmodium 
falciparum (90.5 %). Sixteen patients (42 %) had severe malaria cases and were treated with intravenous artesunate. 
Four patients underwent RBC exchange within a period of 15 h after the first dose of artesunate (range 9–21 h). The 
procedure lasted a median of 2 h (IQR 1.8–2 h), using a median of 12 (IQR 11–14) units of packed RBCs to replace a 
median of 3794 ml (IQR 2977–4343). The technique was well‑tolerated without haemodynamic complications. There 
were no deaths. The regression model showed an estimated time to 95 % decay of 21.6 h (95 % CI 17.3–28.8). When 
assessing effect modification by RBC exchange, there was no difference in the parasite elimination rate (p = 0.286).
Discussion and conclusion: In this study RBC exchange failed to show benefits in terms of parasite clearance prob‑
ably due to the small number of patients analysed. The evidence for exchange transfusion remains limited.
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Background
The management of severe imported malaria remains a 
challenge of consensus, since the elaboration of clini-
cal guidelines always has to deal with the lack of evi-
dence in non-endemic countries. The design of clinical 
trials randomizing cases of severe imported malaria is 
unrealistic nowadays, due to the high number of sub-
jects required, the heterogeneous group of affected 
travellers in terms of parasitaemia and clinical pres-
entation/complications., and ethical problems given 
the evidence from endemic regions [1, 2]. The last 
and most important change in guidelines of imported 
severe malaria is the replacement of quinine by intra-
venous artesunate (IVA) as the first-line therapy [3–
5]. Superior efficacy and reduction of mortality have 
been shown in clinical trials in Asia and Africa [6, 7] 
and confirmed in European retrospective studies [8]. 
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Despite international consensus in using IVA for severe 
malaria, it is not yet available as a licensed drug in all 
non-endemic countries. So far, it is ordered as com-
passionate use or as investigational new drug pro-
tocol. In this context, it is difficult to collect data to 
provide evidence of the safety profile or anti-malarial 
efficacy. Regarding safety profile, some post-introduc-
tion data have suggested delayed haemolytic anae-
mia as an adverse event that should be monitored the 
next 4  weeks after IVA [9–11]. Better data is needed 
in terms of parasite response, which is commonly 
measured through the parasite clearance time (PCT). 
Although parasite clearance has not been validated as 
a surrogate endpoint for death from severe malaria, it 
is an accepted marker of treatment response. PCT50 
is defined as the time required to reduce the initial 
parasitaemia by 50  %, under anti-malarial treatment. 
Improvement of PCT with IVA versus quinine [5–7] 
poses a new scenario that questions the role of some 
adjunctive therapies, such as exchange transfusion and 
red blood cell (RBC) exchange.
Different strategies have been proposed as adjunc-
tive therapies, mainly helping pharmacologic treat-
ment to reduce parasitaemia. Whole blood exchange 
transfusion has been suggested and used with this pur-
pose. Its theoretical benefits are based on the removal 
of: (i) infected circulating red blood cells (RBCs) (those 
sequestered in microvasculature are not affected); (ii) 
rigid non-infected RBCs, with a rheological effect; 
(iii) plasma toxins, minimizing systemic inflamma-
tory response and sequestration. It has demonstrated 
a rapidly reduction in parasite biomass [12], but has 
not shown effectiveness to improve survival [13]. RBC 
exchange has been advocated as a better alternative to 
whole blood exchange transfusion in the adjunctive 
treatment of severe imported malaria [14–16]. RBC 
exchange does not remove plasma toxins, but has sig-
nificant advantages over exchange transfusion in terms 
of speed, efficiency, haemodynamic stability and reten-
tion of plasma components such as clotting factors and 
may thus represent an improvement in adjunctive ther-
apy for severe malaria [17]. Although RBC exchange it is 
recommended by some national apheresis societies [18], 
conclusive evidence is lacking. Some case reports and 
patient cohorts have been reported, but mainly in con-
junction with quinine [14, 19], or using exchange trans-
fusion or RBC exchange [20].
This study reports our experience with the use of 
artesunate for treating severe malaria and the use of RBC 
exchange in selected cases treated at Hospital Clinic of Bar-
celona in Spain between August 2013 and January 2015.
Methods
Study setting and design
This retrospective cohort study includes all patients 
with severe malaria treated with intravenous artesunate 
at Hospital Clínic, in Barcelona, Spain, between August 
2013 and January 2015. Hospital Clínic is a national ref-
erence centre for Tropical Imported Diseases. In 2013, 
artesunate became available in Hospital Clínic for the 
treatment of patients with severe malaria. Patients with 
severe malaria are initially managed in the intensive care 
unit and subsequently, when they have improved, trans-
ferred to a conventional ward.
Study procedures
Patients were diagnosed with severe malaria if their thick 
or thin blood film showed asexual stages of Plasmo-
dium falciparum and fulfilled one or more WHO criteria 
(Table 1). Parasite counts were calculated as a percentage 
of the number of parasitized RBC in a thin blood film. 
Blood films were performed during the clinical manage-
ment of the patient when considered by the treating phy-
sician and until no parasites were observed.
Intravenous artesunate was administered at doses of 
2.4 mg/kg at 0, 12, 24 and then every 24 h until parasi-
taemia was cleared. Intravenous artesunate was followed 
by a course of oral atovaquone-proguanil (1000/400 mg) 
during 3 days.
RBC exchange was performed at the decision of the 
treating physician in conjunction with Haemotherapy 
specialists. In general, it was considered as an adjunctive 
treatment in patients who had high baseline parasitaemia 
(generally above 30 %) and shock, respiratory failure or cer-
ebral malaria. RBC exchange was also performed if patients 
were severely ill and parasitaemia did not decrease at least 
25 % compared to baseline after 8–12 h of artesunate. RBC 
exchanges were performed in a COBE Spectra blood sepa-
rator (TerumoBCT, Lakewood, Co, USA) using the RBCX 
software. Sex, height, weight, patient’s haematocrit, average 
haematocrit in the replacement red blood cells units, desired 
end haematocrit for the patient, fluid balance and the frac-
tion of infected RBC remaining at the end were introduced 
at the start of the procedure. Once the initial data is entered, 
the replacement volume of RBC to be exchanged proposed 
by the COBE Spectra software was followed. ACD-A was 
used as anticoagulant at a infusion rate of 1.2  mL/min/L 
total blood volume with prophylactic calcium and magne-
sium infusion administration [21]. Fresh leukoreduced RBC 
units in SAG-Mannitol additive solution were used as the 
replacement solution. If possible, peripheral vein accesses 
were used for the procedure. If not, a double lumen catheter 
was inserted in the internal jugular vein.
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Data collection
All patients included into the study were identified pro-
spectively in the clinical routine practice. A retrospec-
tive review of their electronic records was performed 
and an anonymized case report form was filled out. This 
included the following data: demographics and travel his-
tory; WHO clinical, analytical and radiological severity 
criteria; dates and times on symptoms initiation, hospital 
attendance, blood films performed and treatment com-
mencement; the number of artesunate doses and other 
antimicrobials previously administered; complications 
and mortality. Data on RBC exchange was provided by 
the Department of Hemotherapy and Hemostasis, which 
keeps a registry of the apheresis performed in the hospital.
Statistical analysis
The data collected were entered into Epi Info 7 (CDC, 
Atlanta, USA) and then transferred to Stata 13.1 (Stata 
Corporation, Texas, USA) for the analysis. Categori-
cal variables were described by counts and percentages, 
whereas median and interquartile ranges (IQR) were 
used to summarize continuous variables. Comparisons 
between groups were performed with Fisher exact test 
and Mann–Whitney test for categorical and continuous 
variables, respectively.
Parasite clearance times (PCT) were estimated since 
the administration of the first dose of artesunate. Ini-
tially, the parasite loads were calculated from the para-
site counts expressed in percentages and the number of 
RBC per microlitre in each blood film. The variation of 
parasite loads was analysed using a log-linear mixed-
effects regression model incorporating a Gaussian ran-
dom intercept. This resulted in an estimation of the 
dynamics of parasitaemia, assuming a single exponential 
model, allowing calculating the decrease of log parasitae-
mia per unit of time (hour) or parasite elimination rate. 
The interaction between RBC exchange and time was 
included in the model to evaluate the possible modifica-
tion of the effect of artesunate in clearing parasitaemia.
The average reduction rate per hour was obtained 
based on the coefficient of the regression model (1- expo-
nential of the coefficient of regression), as well as its 
95 % confidence interval. The model estimates obtained 
were used to calculate the time to 50 % (PCT50 %), 75 % 
(PCT75 %), 90 % (PCT90 %), 95 % (PCT95 %) and 99 % 
(PCT99  %) clearance of parasitaemia. 95  % confidence 
intervals (95 % CI) and p values were obtained for all esti-
mates in the model.
Ethical considerations
The Ethics Committee of Hospital Clínic approved this 
study. Data collection forms were completely anony-
mous. As it was a retrospective study, the Ethics Com-
mittee approved waiver of individual consent from 
patients whose routine data was used.
Results
Patients’ baseline characteristics
From August 2013 to January 2015, 42 patients presented 
with malaria, 38 by P. falciparum (90.5  %), and 16 of 
Table 1 Severity criteria in Plasmodium falciparum malaria
Adapted from World Health Organization [2]
Type Criteria Definition
Clinical Impaired consciousness Any impairment in consciousness, not related to other causes 
(hypoglycaemia, concomitant infection)
Prostration Generalized weakness so that the patient is unable to sit, stand or 
walk without assistance
Multiple convulsions More than two episodes within 24 h
Respiratory failure PaO2 <60 mmH (FiO2 21 %)
Shock Systolic blood pressure <80 mmHg
Jaundice Clinical jaundice plus evidence of other vital organ dysfunction
Bleeding Spontaneous bleeding without any other potential cause
Analytical and radiological Hypoglycaemia <2.2 mmol/l or <40 mg/dl
Metabolic acidosis Plasma bicarbonate <15 mmol/l
Severe normocytic anaemia Haemoglobin <5 g/dl
Haemoglobinuria Haemoglobin in urine
Hyperlactataemia Lactate >5 mmol/l
Renal impairment Serum creatinine >265 µmol/l
Pulmonary oedema or distress respiratory  
syndrome
Bilateral alveolar infiltrates in chest x‑ray
Parasitological Hyperparasitaemia Parasitaemia >2.5 %
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those (42.11  %) were identified as severe malaria cases. 
All 16 were treated with IVA, and 4 additionally with 
RBC exchange. Their baseline characteristics are summa-
rized and compared in Table 2.
The median age was 40 years old (IQR 33–50), with a 
high proportion of male patients (11/16, 68.75 %). Most 
patients were travellers who had arrived from sub-Saha-
ran Africa (11/16, 68.70 %), followed by immigrants “vis-
iting friends and relatives”—temporary visitors- (VFR) 
(3/16, 18.75  %). None of the travellers completed a full 
course of chemoprophylaxis. Two patients were residents 
in endemic countries travelling to Spain (2/16, 12.50 %).
Half of the cohort presented three or more sever-
ity criteria, the most frequent being hyperparasitaemia 
(93.75 %), prostration (50 %), renal impairment (37.50 %) 
and jaundice (37.50  %). The median time to seek for 
health advice was 5  days (range 2.50–11.70) since the 
onset of symptoms. The median initial parasitaemia was 
12.5  % (range 3.95–32.50  %). Four patients (25  %) pre-
sented with an initial parasitaemia above 30 %.
Patients finally treated with RBC exchange had a higher 
median initial parasitaemia compared to those who were 
treated with IVA alone (46.50 vs 7.30  %) and presented 
with more severity criteria (Table 2).
RBC exchange and outcome
Four patients (25 %) received RBC exchange as an adjunc-
tive treatment to IVA. This technique was initiated a 
median of 15.45 h after the first dose of IVA (IQR 9.05–
20.58). The median duration of the technique was 2 h (IQR 
1.80–2), using a median of 12 units of packed RBCs (IQR 
11–14) to replace a median of 3794 ml (IQR 2977–4343).
The procedure was well tolerated without haemody-
namic or hydroelectrolytical complications. The median 
difference in haematocrit and platelet count before 
and after RBC exchange was 2  % and −13,500/mm3, 
Table 2 Characteristics of 16 patients with severe malaria treated with artesunate with or without RBC exchange
Categorical variables are described by counts and percentages; continuous variables are expressed as median (interquartile range)
RBC red blood cell
a Data available only for 15 participants
Overall (n = 16) Artesunate only  
(n = 12)




 Age 40 (33–50) 36 (32–48) 47 (39–55) 0.332
 Male 11 (68.75) 8 (66.67) 3 (75) 0.755
Clinical data
 Number of severity criteria 3 (1–6) 1 (1–5) 7 (6–10) 0.016
Clinical criteria
 >2 criteria 6 (37.5) 3 (25) 3 (75) 0.074
 Impaired consciousness 3 (18.75) 2 (16.67) 1 (25) 0.712
 Postration 8 (50) 5 (41.67) 3 (75) 0.248
 Multiples convulsions 0 (0) 0 (0) 0 (0) –
 Respiratory failure 3 (18.75) 1 (8.33) 2 (50) 0.064
 Shock 4 (25) 3 (25) 1 (25) 1
 Jaundice 6 (37.50) 2 (16.67) 4 (100) 0.003
 Bleeding 3 (18.75) 2 (16.67) 1 (25) 0.712
Analytical and radiological criteria
 ≥2 criteria 7 (43.75) 3 (25) 4 (100) 0.009
 Hypoglycaemia 2 (12.50) 1 (8.33) 1 (25) 0.383
 Metabolic acidosis 4 (25) 1 (8.33) 3 (75) 0.008
 Severe normocytic anaemia 0 (0) 0 (0) 0 (0) –
 Haemoglobinuriaa 4 (26.67) 2 (16.67) 2 (66.67) 0.080
 Hyperlactataemiaa 2 (13.33) 0 (0) 2 (66.67) 0.002
 Renal impairment 6 (37.50) 2 (16.67) 4 (100) 0.003
 Pulmonary oedema 3 (18.75) 1 (8.33) 2 (50) 0.064
Parasitological data
 Parasitaemia (%) 12.5 (3.95–32.5) 7.3 (3.85–19.50) 46.5 (34–57) 0.008
 Parasitaemia >30 % 4 (25) 1 (8.33) 3 (75) 0.008
 Hyperparasitaemia 15 (93.75) 11 (91.67) 4 (100) 0.551
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respectively. The median difference in blood calcium and 
potassium before and after the procedure was 0.15  mg/
dl and −0.2  mmol/l, respectively. All patients survived 
and none of them had long-term renal or neurologi-
cal sequelae. Two cases of delayed haemolysis could be 
detected: they completely recovered and did not show 
more complications.
Parasite clearance times
The values of parasitaemia at each timepoint for each 
patient were analysed to estimate the PCT (Fig.  1). 
Table 3 summarizes the estimates from the mixed effects 
regression model including the effect of time on parasite 
clearance, thus obtaining the parasite elimination rate. 
The results of the model suggested that parasitaemia 
significantly decreased in relation with time. Accord-
ing to the estimated coefficient, the average reduction 
rate was 12  % per hour (95  % CI 10–14, p  <  0.0001). 
Patients who received RBC exchange as an adjunctive 
therapy had a higher baseline parasitaemia compared to 
those who had IVA alone (p  <  0.0001). When assessing 
effect modification by RBC exchange in the model, there 
was not any difference in the parasite elimination rate 
(coefficient for interaction 0.03, 95  % CI −0.02; 0.08, 
p = 0.2861).
Based on the estimates of this model, the mean time 
to 50 % (PCT50), 90 % (PCT90), 95 % (PCT95) and 99 % 
(PCT99) parasite clearance were calculated (Table  4). 
PCT were calculated for the whole cohort without strati-
fying between those who had RBC exchange or not, since 
there was no evidence of an interaction between this 
therapy and time. Interestingly, 95 % of initial parasitae-
mia was cleared in a mean time of less than 24 h (21.60, 
95 % CI 17.30–28.80), and almost the whole initial par-
asitaemia was cleared in less than 36  h (33.21, 95  % CI 
26.60–44.30).
Discussion
In the present study, it is shown in the largest case series 
of severe imported malaria that use RBC exchange in a 
cohort treated with artesunate that IVA reduces quickly 
parasitaemia and that RBC exchange does not seem to 
add any benefit in terms of parasite clearance times.
The results of this retrospective follow-up study con-
firm the speed of action of IVA when used for imported 
severe falciparum malaria, reducing parasite clear-
ance time in a similar way to other cohorts [5–7]. This 
case series, due to the mathematical population model 
applied, provides valuable data about parasite kinetics 
during the response to treatment. Due to the small sam-
ple size, the regression model was estimated assuming 
linear reduction of parasite density and, therefore, the 
real reduction could be underestimated at early times. 
The PCT included in this article can be used in the 
clinical practice by physicians treating imported severe 
malaria, as a reference for monitoring the microbiologi-
cal answer to IVA.
Fig. 1 a Parasitaemia dynamics during the first 72 h under treatment 
with artesunate expressed as parasite load. b Parasitaemia dynamics 
expressed as the proportion of the baseline parasitaemia
Table 3 Mixed-effects regression model to  estimate the 
changes in parasitaemia in 16 patients with severe malaria
RBC red blood cell
a Log initial parasitaemia for individuals who did not receive RBC exchange 
(intercept of the regression model)
b Difference in log initial parasitaemia for individuals who received RBC 
exchange vs those who did not
c Difference in log parasitaemia per unit increase of time (hour)





12.02 11.24; 12.79 <0.0001
RBC exchangeb 2.47 1.43; 3.51 <0.0001
Parasite elimination  
rate (/h)c
−0.13 −0.15; −0.10 <0.0001
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Regarding the use of RBC exchange as an adjunctive 
therapy, it was found that it does not significantly con-
tribute to parasite clearance [20]. However, this conclu-
sion has to be taken very cautiously. First, small sample 
size and the study design may be responsible for this lack 
of evidence for the effect of the adjunctive therapy. Fur-
thermore, the endpoint of the study was parasite clear-
ance alone, which does not allow any firm conclusion 
for other biological plausible benefits of RBC exchange. 
Finally, the fact that the treatment protocol at this insti-
tution indicates RBC exchange for only selected patients 
may have reduced the effect modification of RBC 
exchange (selection bias).
In this study, a mixed effects model for log parasitaemia 
with fixed and random effects for initial parasitaemia, 
and fixed effects for exchange transfusion and time was 
used (Table 3). The authors were unable to demonstrate 
an effect of exchange transfusion on the decay of para-
sitaemia, as addition of an interaction between exchange 
transfusion and time was non-significant. This may have 
been due to the small sample size.
The development of safer apheresis therapies that can be 
used for severe malaria, such as RBC exchange, may have 
an impact on the medical management of the disease and 
there are many aspects of its use as adjunctive therapy sus-
ceptible of further investigation. One of the main questions 
about using RBC exchange for severe malaria together 
with IVA is which would be the accurate moment to ini-
tiate the apheresis. There is no debate that anti-malarial 
drug is the first step for this medical emergency. Its use 
is envisioned due to its good safety profile, confirmed by 
the data in this cohort, and its plausible biological ben-
efits. One of the hypothetical concerns when using RBC 
exchange immediately after AVI is that the drug could be 
partially removed within the RBC exchange since artesu-
nate has shown to have high binding to RBC [22].
Therefore, the use of RBC exchange should target to 
optimize IVA effect, not to replace it, not even dimin-
ish it. Since artesunate half-life is less than 15  min and 
30–60 min for its metabolite dihydroartemisinin [23], the 
recommendation would be initiating RBC exchange not 
earlier than 3–4 h after initiating AVI. Due to its mech-
anism of action and its stage-specificity, artesunate gen-
erates more “once-parasitized” RBC than quinine when 
used in cases of severe malaria [24]. These RBC are eryth-
rocytes whose parasite has been removed, by the spleen or 
by artesunate, becoming less mobile, spherical and partic-
ulate cell. The “pitting” effect explains disparity between 
haematocrit decrease and parasite count decay, as well as 
the rapid effect of artesunate [25]. One of the hypotheses 
is that once-parasitized RBC are major contributors to 
the development of post-artesunate delayed haemolysis 
(PADH) [11]. In this cohort of patients, just two cases of 
delayed haemolytic anaemia were detected, with no rela-
tion to RBC exchange. The authors hypothesize whether 
RBC exchange may prevent delayed anaemia with IVA.
Conclusions
This case series illustrates the experience with the use 
of AVI for treating severe malaria, and the use of RBC 
exchange as adjunctive therapy. No serious adverse 
effects of RBC exchange transfusion were encountered in 
this small series. The study provides valuable data about 
technical procedure of RBC exchange and about moni-
toring microbiological response to artesunate. Although 
there remains limited evidence to support RBC exchange 
transfusion in severe malaria, it may be considered in 
special circumstances, such as the suspicion of arte-
misinin resistant hyperparasitemic falciparum malaria, 
the unavailability of IVA or in settings where parasite 
clearance may be prolonged, such as splenectomy.
A randomized clinical trial would provide some evi-
dence about the prompt indication and initiation of RBC 
exchange when using artesunate, but it is currently unaf-
fordable. Further multicentric, cohort studies should be 
performed to gradually increase the level of evidence to 
determine which selected patients with imported severe 
malaria may benefit from this adjunctive treatment and 
at which moment after artesunate administration will not 
reduce the drug’s benefit.
Table 4 Mean parasite clearance times estimated from the mixed-effects model in 16 patients with severe malaria
Data expressed as hours
PCT parasite clearance time
% All patients  
(95 % CI) n = 16
Artesunate only  
(95 % CI) n = 12
Artesunate and RBC 
exchange (95 % CI) n = 4
PCT 50 5.0 (4.0–6.7) 5.0 (4.0–6.7) 6.3 (4.6–9.7)
PCT 75 10.0 (8.0–13.3) 10.0 (8.0–13.3) 12.6 (9.3–19.4)
PCT 90 16.6 (13.3–22.1) 16.6 (13.3–22.1) 20.9 (15.4–32.3)
PCT 95 21.6 (17.3–28.8) 21.6 (17.3–28.8) 27.2 (20.1–42.0)
PCT 99 33.2 (26.6–44.3) 33.2 (26.6–44.3) 41.7 (30.9–64.5)
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